vs
ALTISOURCE PORTFOLIO SOLUTIONS S.A.（ASPS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ALTISOURCE PORTFOLIO SOLUTIONS S.A.的季度营收约是REGENXBIO Inc.的1.4倍（$42.3M vs $30.3M），ALTISOURCE PORTFOLIO SOLUTIONS S.A.净利率更高（-16.8% vs -221.3%，领先204.5%），REGENXBIO Inc.同比增速更快（43.0% vs 3.2%），ALTISOURCE PORTFOLIO SOLUTIONS S.A.自由现金流更多（$-525.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 3.6%）
Altisource Portfolio Solutions S.A.是面向抵押贷款、房地产及消费金融领域的全球服务商，为贷款机构、服务商、投资者等市场参与者提供技术、数据与运营解决方案，优化资产管理、房产交易等业务流程，提升客户运营效率。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ASPS vs RGNX — 直观对比
营收规模更大
ASPS
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出39.8%
3.2%
净利率更高
ASPS
高出204.5%
-221.3%
自由现金流更多
ASPS
多$52.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $42.3M | $30.3M |
| 净利润 | $-7.1M | $-67.1M |
| 毛利率 | 26.5% | — |
| 营业利润率 | -15.5% | -190.0% |
| 净利率 | -16.8% | -221.3% |
| 营收同比 | 3.2% | 43.0% |
| 净利润同比 | 18.2% | -31.2% |
| 每股收益（稀释后） | $-1.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPSRGNX
| Q4 25 | $42.3M | $30.3M | ||
| Q3 25 | $41.9M | $29.7M | ||
| Q2 25 | $43.3M | $21.4M | ||
| Q1 25 | $43.4M | $89.0M | ||
| Q4 24 | $41.0M | $21.2M | ||
| Q3 24 | $40.5M | $24.2M | ||
| Q2 24 | $39.1M | $22.3M | ||
| Q1 24 | $39.5M | $15.6M |
净利润ASPSRGNX
| Q4 25 | $-7.1M | $-67.1M | ||
| Q3 25 | $-2.3M | $-61.9M | ||
| Q2 25 | $16.7M | $-70.9M | ||
| Q1 25 | $-5.3M | $6.1M | ||
| Q4 24 | $-8.7M | $-51.2M | ||
| Q3 24 | $-9.3M | $-59.6M | ||
| Q2 24 | $-8.3M | $-53.0M | ||
| Q1 24 | $-9.2M | $-63.3M |
毛利率ASPSRGNX
| Q4 25 | 26.5% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 30.1% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 30.3% | 70.2% | ||
| Q3 24 | 29.8% | 48.8% | ||
| Q2 24 | 32.5% | 52.5% | ||
| Q1 24 | 31.2% | 72.6% |
营业利润率ASPSRGNX
| Q4 25 | -15.5% | -190.0% | ||
| Q3 25 | 1.2% | -176.3% | ||
| Q2 25 | 7.5% | -296.3% | ||
| Q1 25 | 7.5% | 13.6% | ||
| Q4 24 | 1.4% | -242.1% | ||
| Q3 24 | 2.7% | -256.6% | ||
| Q2 24 | 5.3% | -251.3% | ||
| Q1 24 | -1.4% | -408.8% |
净利率ASPSRGNX
| Q4 25 | -16.8% | -221.3% | ||
| Q3 25 | -5.5% | -208.3% | ||
| Q2 25 | 38.5% | -331.8% | ||
| Q1 25 | -12.1% | 6.8% | ||
| Q4 24 | -21.3% | -241.3% | ||
| Q3 24 | -23.0% | -246.3% | ||
| Q2 24 | -21.1% | -237.7% | ||
| Q1 24 | -23.2% | -405.4% |
每股收益（稀释后）ASPSRGNX
| Q4 25 | $-1.02 | $-1.30 | ||
| Q3 25 | $-0.22 | $-1.20 | ||
| Q2 25 | $1.48 | $-1.38 | ||
| Q1 25 | $-0.09 | $0.12 | ||
| Q4 24 | $-4.72 | $-0.99 | ||
| Q3 24 | $-2.61 | $-1.17 | ||
| Q2 24 | $-2.33 | $-1.05 | ||
| Q1 24 | $-0.33 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.6M | $230.1M |
| 总债务越低越好 | $191.1M | — |
| 股东权益账面价值 | $-110.2M | $102.7M |
| 总资产 | $139.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASPSRGNX
| Q4 25 | $26.6M | $230.1M | ||
| Q3 25 | $28.6M | $274.2M | ||
| Q2 25 | $30.0M | $323.3M | ||
| Q1 25 | $30.8M | $267.9M | ||
| Q4 24 | $29.8M | $234.7M | ||
| Q3 24 | $28.3M | $255.5M | ||
| Q2 24 | $29.7M | $290.4M | ||
| Q1 24 | $29.6M | $338.7M |
总债务ASPSRGNX
| Q4 25 | $191.1M | — | ||
| Q3 25 | $192.5M | — | ||
| Q2 25 | $193.9M | — | ||
| Q1 25 | $195.0M | — | ||
| Q4 24 | $230.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPSRGNX
| Q4 25 | $-110.2M | $102.7M | ||
| Q3 25 | $-104.2M | $161.5M | ||
| Q2 25 | $-102.7M | $213.7M | ||
| Q1 25 | $-119.8M | $274.2M | ||
| Q4 24 | $-157.4M | $259.7M | ||
| Q3 24 | $-149.4M | $301.4M | ||
| Q2 24 | $-140.8M | $348.3M | ||
| Q1 24 | $-133.3M | $390.7M |
总资产ASPSRGNX
| Q4 25 | $139.8M | $453.0M | ||
| Q3 25 | $139.9M | $525.2M | ||
| Q2 25 | $142.9M | $581.0M | ||
| Q1 25 | $145.7M | $490.9M | ||
| Q4 24 | $143.6M | $466.0M | ||
| Q3 24 | $144.5M | $519.1M | ||
| Q2 24 | $146.6M | $569.4M | ||
| Q1 24 | $148.9M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-505.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-525.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -1.2% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-5.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ASPSRGNX
| Q4 25 | $-505.0K | $-52.3M | ||
| Q3 25 | $718.0K | $-56.0M | ||
| Q2 25 | $-306.0K | $-49.3M | ||
| Q1 25 | $-5.0M | $33.6M | ||
| Q4 24 | $-1.4M | $-31.6M | ||
| Q3 24 | $-1.6M | $-40.5M | ||
| Q2 24 | $180.0K | $-45.5M | ||
| Q1 24 | $-2.2M | $-55.5M |
自由现金流ASPSRGNX
| Q4 25 | $-525.0K | $-52.8M | ||
| Q3 25 | $697.0K | $-56.5M | ||
| Q2 25 | $-309.0K | $-49.7M | ||
| Q1 25 | $-5.0M | $32.6M | ||
| Q4 24 | $-1.4M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率ASPSRGNX
| Q4 25 | -1.2% | -174.0% | ||
| Q3 25 | 1.7% | -189.9% | ||
| Q2 25 | -0.7% | -232.8% | ||
| Q1 25 | -11.5% | 36.6% | ||
| Q4 24 | -3.4% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度ASPSRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率ASPSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPS
| Services | $39.9M | 94% |
| Revenue Relatedto Technology Platformsand Professional Services | $2.4M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
